Stockfry.comSAS Online Stock Trading, Demat, Brokerage and Reviews  Rs 999 Unlimited Trades
Enquire Now

Sun Pharmaceutical Industries Ltd BSE:524715 NSE:SUNPHARMA

Sun Pharmaceutical Industries Ltd is engaged in Healthcare/Hospitals business. Company is listed on both NSE and BSE. NSE symbol for Sun Pharmaceutical Industries Ltd is 'SUNPHARMA' and BSE code for Sun Pharmaceutical Industries Ltd is '524715'.

About Company

Sun Pharmaceutical Industries Limited makes specialty pharmaceuticals and active pharmaceutical ingredients (API). The Company`s brands are prescribed in chronic therapy areas, such as cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. The Company manufactures a range of APIs, including complex actives like anticancer, steroids, peptides and hormones. It also develops bulk actives through non-infringing routes in various therapeutic areas. It markets over 740 products across 26 countries. During the fiscal year ended march 31, 2006 (fiscal 2006), domestic formulations (the sales of specialty prescription brands) in India, were 55% of total revenues.

Sun Pharmaceutical Industries Ltd Stock Quotes and Charts

Symbol Last Trade on
Change Volume
Open High Low
  Previous Day's   52 Weeks
Close Low - High
  Industry*   Healthcare/Hospitals
  Corporate Action  Detail/More>>


Sun Pharmaceutical Industries Ltd User Reviews

3. Insight technical  Jun 19, 2009 1:55:46 PM IST Reply

Sun Pharma<br>Buy<br>Price : Rs 1,297 Target Price (Mar 10): Rs 1,530 <br><br>Caraco 10-K analysis<br><br>* FY09 pantoprazole sales at c. $150m: Distributed sales for the full year at $225m is flat YoY and includes c. $150m pantoprazole. The manufactured products sales at $112m were down c.10% YoY in FY09. We believe that given the strong guidance of 13-15% sales growth Sun would continue to sell pantoprazole in current fiscal and have estimated c. $100m sales.<br><br>* Manufactured products sales declined 37% in 4Q09: 4Q09 manufactured products sales were impacted by product recalls totaling $4.2m and non-renewal of contracts with US Veteran Administration. These recalls have reduced profits by $4.7m in 4Q09. Adjusting for this, manufactured products and total gross margins would be c.49% and c.20% respectively for 4Q09. Company expects challenges to continue to impact near term sales in these products.<br><br>* Distributed inventories decline sharply in 4Q09: Distributed inventories in Caraco at the end of FY09 at $13.3m are down 82% from $75m in 3Q09. Overall inventory level is down from $298m to $80m at end of FY09. Caraco bought goods worth c. $8.4m from Sun in FY09.<br><br>* …though receivables remain flat QoQ: Accounts receivables ending FY09 at $15m are marginally up from $13m in Q309, but significantly below FY08 end level at $136m. The overall reduction in debtors has also led to c.90% reduction in payables to Sun Pharma. Payables to Sun have decreased from $388m in FY08 to $44m in FY09 (down 35% sequentially from $69m in Q309).<br><br>* FDA issue status unchanged: Caraco received 483s in its May 2009 inspection following warning letter issued in October 2008. These 483s pertain to inventories and recall/compliance but not to quality control lab. Caraco hasn’t received FDA approval for its ANDAs since 1Q09 and it is unlikely that it will receive any approval till FDA reviews the corrective response. We expect a delay of at least six months, as a reinspection is likely.<br><br><br>

2. insight  Nov 11, 2009 12:10:08 PM IST Reply

Sun Pharma<br>Under Review<br>Price: Rs1,404 Target Price: Under Review<br><br>Caraco 10-Q: Pantoprazole up again<br><br>* Distributed sales up 117% QoQ: Caraco 10Q for quarter ending<br>September 09 is now available. Of the total reported sales of $78.4m,<br>distributed products sales in 2QFY10 are at $75.9m. This is significantly<br>higher than sales in 1Q10 at $34.9m. In addition the pantoprazole sales<br>at c. $60m are again higher than our estimate of $25m. For the 1H10,<br>pantoprazole cumulative sales at c. $82m form c. 65% of the overall<br>net sales. We believe that with higher para-IV sales, adjusted net profit<br>could be significantly lower than guided Rs3.2bn. The base<br>manufactured product sales at $2.49m are continually affected by<br>inventory seizure at Michigan facility and partly due to voluntary<br>product recalls taken in March-09.<br><br>* Distributed inventories are maintained: Distributed inventories at<br>$46.4m include higher levels of inventory related to para-IV products to<br>support anticipated sales in near term. Higher sales of distributed<br>products have been supported by increase in accounts payable to Sun<br>Pharma which have increased from $84.2m to $114.9m. Accounts<br>receivables have also increased in 2Q10.<br><br>* “One-offs” exact nature still not clear: We estimate c. $33-35m<br>income from Forest deal in 2Q10. This includes $3-5m income from<br>reimbursement of certain litigation costs, $20m non-recurring income<br>and additional estimated $10m income in other income which was<br>higher in 2Q10. This was offset by one-off expenses which were onetime<br>separation payment of c. $0.9m to former CEO, legal fees related<br>to FDA issues and certain customer related costs in SGA and $7.4m<br>inventory charge for seizure by FDA. While the exact nature of all the<br>one-offs is not clear we believe that there is an overall net gain of c.<br>$20m in US business.<br><br>* Outlook includes higher reliance on distributed sales: Caraco<br>expects cessation to continue until it receives notification from experts<br>and FDA after assessing its compliance under Consent Decree.<br>However, company expects to maintain sales on back of distributed<br>products and products manufactured by third parties. In 1H10, 9 new<br>distributed products were launched. It recently launched ketorolac<br>tromethamine ophthalmic solution following Sun`s ANDA approval on<br>first day post expiry. The company is also considering site transfer for<br>some of the products under seizure. In addition in line with product<br>development, Caraco entered into agreement with Alkaloida Chemicals<br>in July 09, under which it will use product know-how and technology<br>from Alkaloida for development of its ANDAs and pay 10% royalty on<br>net sales.<br><br>Note: More intra-day opportunities will be provided<br>live during the market hours<br><br>Contact : +91 982222686<br><br>indian share market tips,nifty option trading,nifty option,intaday option trading,nifty option,nse market tips,nse/bse stock tips,trading recommendations of indian stocks,indian share market,stock market recommendations by sms,pre-market analysis company<br><br>hot shares in bse,sharemarketindia,hot stocks bse,nse hot stocks,preferred stock recommendations,hot shares on bse,intraday stock recommendations,technicals of share market,mcxtip,indian stock advisory,nifty stock recomendations,stock trading franchise india,stock market trend history,bse option calculator,hot stocks in indian share market,hot tips bse market free sms,indianstockcharts,hot indian stocks,hot intraday tips nse,hot intraday tips nse bse,indian stock recommendation for intraday,nifty stock recommendations,technical share market,technicals of indian stocks,gold intraday tips,mcx broker tips,hot stock in nse,hot stocks in bse,indian technicals,intraday option trading tips,nri intraday trading,nse intraday recommendations,option calculator nse,share market recommendations,stock market consultant,ncdex tips

1. Rahul Dixit  Jun 13, 2013 12:16:50 PM IST Reply

Sell SUNPHARMA June future below 962 Target 942 stop loss 980.<br><br>Copy paste URL

ProStocks, The Flat Rate Discount Stock Broker

Fix Price - Rs 15 Per Trade

Rs 899/Month,8999/Year for
Equity Cash and F&O

Rs 499/Month,4999/Year for
Currency Derivatives

Lowest Transaction Charge
Lowest Call & Trade Fee
Lowest Stamp Duty

Get FREE Trading + Demat Acct

Zerodha  Zerodha

Free Equity Delivery Trades
Flat Rs 20 Per Trade for F&O

SAS Online Stock Trading, Demat, Brokerage and Reviews  SAS Online

Rs 999 for Unlimited Trading

Get Free Trading Account


Brokerage: Intraday @ 0.02%, Delivery @ 0.15%

Rs 0 account opening fee
(400 Rs waived)


Beginner, seasoned investor, active trader or HNI. Get customised solutions.

Rs 0 account opening fee on Online Trading and a Demat Account
(Rs 1150 waived)